Apotex Inc. – FDA Warning Letter, May 9, 2025

The FDA issued a Warning Letter to Apotex Inc. following an inspection of its Richmond Hill drug manufacturing facility from April 28 to May 9, 2025. The letter highlights significant violations of Current Good Manufacturing Practice (CGMP) regulations (21 CFR parts 210 and 211), rendering the company"s drug products adulterated under the Federal Food, Drug, and Cosmetic Act.

Key violations include a systemic failure to thoroughly investigate unexplained discrepancies and batch failures. Apotex inadequately investigated critical equipment failures, such as repeated leak testing failures on a filling machine, and container-closure integrity issues for various drug products, leading to product leakage and potential impact on distributed batches. The FDA noted a pattern of production personnel repeatedly performing tests until passing results were obtained, rather than addressing root causes.

Additionally, the company failed to establish and follow appropriate written procedures to prevent microbiological contamination in its sterile drug manufacturing. This included inadequate cleaning, decontamination, and maintenance of aseptic processing equipment, specifically observing deteriorated components, unaddressed discolorations, and improper decontamination techniques for an isolator.

The FDA deemed Apotex"s response to the inspection inadequate, citing a reactive approach that failed to address the underlying systemic issues. Required actions include a comprehensive, independent assessment and remediation plan for the firm"s deviation investigation system, covering root cause analysis, CAPA effectiveness, and quality unit oversight. An independent assessment and remediation plan for the entire Corrective and Preventive Action (CAPA) program is also mandated to ensure robust quality assurance.